Skip to main content

Table 4 Healthcare costs among FN patients and matched comparison patients

From: Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin’s lymphoma in European and Australian clinical practice

Healthcare Resources Mean (95% CI), in British pounds
Overall* Index Cycle Post-Index Cycles
FN Patients (n = 295) Comparison Patients (n = 295) Difference FN Patients (n = 295) Comparison Patients (n = 295) Difference FN Patients (n = 295) Comparison Patients (n = 295) Difference
Total Cost of FN, Overall 8,066(7,277, 8,882) 2,290(1,923, 2,655) 5,776(4,928, 6,713) 4,051(3,633, 4,485) --- 4,051(3,633, 4,485) 4,015(3,374, 4,724) 2,290(1,923, 2,655) 1,725(978, 2,498)
Inpatient Care 6,007(5,278, 6,771) 543(287, 858) 5,463(4,709, 6,322) 3,942(3,520, 4,372) --- 3,942(3,520, 4,372) 2,065(1,478, 2,694) 543(287, 858) 1,522(900, 2,180)
Outpatient Care 180(123, 252) 130(56, 219) 50(−37, 144) 65(43, 89) --- 65(43, 89) 115(62, 182) 130(56, 219) −15 (−97, 74)
Home Care 1,673(1,452, 1,899) 1,447(1,220, 1,674) 225(−78, 545) 41(26, 59) --- 41(26, 59) 1,632(1,409, 1,853) 1,447(1,220, 1,674) 184(−117, 503)
Other/Unknown Care 207(135, 293) 169(97, 253) 38(−67, 152) 4(2, 5) --- 4(2, 5) 203(131, 289) 169(97, 253) 34(−71, 148)
Total Cost of FN, by Setting of Care
Inpatient Episode 9,688(8,709, 10,653) 2,430(1,984, 2,931) 7,259(6,327, 8,205) 5,281(4,810, 5,774) --- 5,281(4,810, 5,774) 4,407(3,613, 5,225) 2,430(1,984, 2,931) 1,978(1,262, 2,801)
Outpatient Episode 3,761(1,908, 6,007) 1,777(1,116, 2,565) 1,984(−193, 4,177) 341(293, 435) --- 341(293, 435) 3,420(1,529, 5,676) 1,777(1,116, 2,565) 1,644(−521, 3,853)
Home Episode 3,291(2,445, 4,339) 1,826(993, 2,919) 1,466(234, 2,495) 324(241, 415) --- 324(241, 415) 2,967(2,124, 4,059) 1,826(993, 2,919) 1,141(−99, 2,176)
Other/Unknown Episode 2,211(1,140, 3,425) 1,850(766, 3,157) 361(−956, 1,650) 104(51, 205) --- 104(51, 205) 2,107(1,052, 3,333) 1,850(766, 3,157) 258(−1,031, 1,558)
  1. *Mean costs from index cycle through end of the chemotherapy course.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us